13F Holdings
中文EN

DNA Ginkgo Bioworks Holdings, Inc.

Biological Products, (No Diagnostic Substances) · NYSE · SEC CIK 1830214 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-33.1%
TTM net income YoY26.1%
TTM EPS YoY—
Revenue 3-yr CAGR-31.6%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-242.5%
Net margin-249.2%
FCF margin-172.3%
EBITDA margin-190.5%

Returns

ROE-52.7%
ROA-23.5%
ROIC (approx.)-51.0%
Asset turnover0.09x

Leverage & solvency

Liabilities / assets58.4%
Debt / equity0.00x
Current ratio4.72x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.67x
Accruals ratio-7.9%
Payout ratio—
Capex / revenue6.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$170.16M$227.04M$251.46M$477.71M$313.84M
R&D expense$243.77M$424.06M$580.62M$1.05B$1.15B
SG&A expense$183.29M$246.16M$385.02M$1.43B$862.95M
Operating income-$315.28M-$559.76M-$864.41M-$2.21B-$1.83B
Interest expense$0$94,000$93,000$106,000$2.37M
Pretax income-$313.60M-$547.51M-$892.94M-$2.12B-$1.84B
Income tax-$837,000-$479,000-$71,000-$15.03M-$1.48M
Net income-$312.76M-$547.03M-$892.87M-$2.10B-$1.83B
EBITDA-$256.29M-$496.74M-$793.90M-$2.17B-$1.80B
EPS (basic)-5.64-10.54-18.37-50.15-1.35
EPS (diluted)-5.64-10.54-18.37-50.20-1.39
Weighted avg. shares (diluted)55.46M51.89M48.61M42.00M1.36B
Banking
Net interest income————-$9.65M
Loans, net$9.70M$25.10M$21.00M$7.50M—
Balance sheet
Cash & equivalents$167.20M$561.57M$944.07M$1.32B$1.55B
Short-term investments$255.42M$0———
Receivables$24.03M$21.86M$17.16M$80.91M$131.54M
Inventory——$46,000$4.36M$3.36M
Current assets$471.84M$602.74M$1.00B$1.45B$1.72B
PP&E, net$167.37M$203.72M$188.19M$314.77M$145.77M
Goodwill—$0$49.24M$60.21M$21.31M
Intangibles$53.48M$72.51M$82.74M$111.04M$21.64M
Total assets$1.12B$1.38B$1.67B$2.54B$2.07B
Current liabilities$95.97M$107.27M$163.86M$172.96M$134.76M
Total liabilities$611.11M$661.39M$568.19M$803.04M$503.61M
Shareholders' equity$508.59M$716.06M$1.10B$1.74B$1.51B
Shares outstanding58.21M54.37M50.03M1.89B1.61B
Cash flow statement
Operating cash flow-$171.06M-$319.58M-$295.50M-$252.20M-$253.82M
Capital expenditure$7.67M$62.54M$40.80M$52.27M$56.52M
Free cash flow-$178.72M-$382.13M-$336.30M-$304.47M-$310.34M
Investing cash flow-$240.29M-$62.24M-$80.69M-$67.39M-$73.26M
Financing cash flow$17.77M-$1.74M-$3.22M$95.34M$1.53B
Depreciation & amortization$58.99M$63.02M$70.51M$42.55M$29.08M
Stock-based compensation$81.55M$112.34M$229.88M$1.93B$1.61B

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.